Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...
When a renowned Israeli TV journalist lost his ability to speak clearly because of ALS, he thought his career might be over.
Eli Lilly partnership aims to identify new treatments for ALS based on antibodies from people with very slow disease ...
company is now working on screening, enrollment and dosing for a Phase 1 trial of AMX0114, a drug for people living with ALS--amyotrophic lateral sclerosis--a fatal disease that triggers ...
Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...
Today on Louisiana Considered, an ALS patient and advocate tells us about the crucial role caregivers play in supporting ...
Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...
A New Bedford man was sentenced to prison for conspiring to steal and then depositing over $450,000 from a U.S. Marine ...
Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to ...
The company in March said its ALS drug Relyvrio had failed a late-stage clinical trial, and the stock has sunk more than 78% over the past year. Amylyx pulled Relyvrio from the market, cut its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback